Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Hosted on MSN15d
New treatment option shows promise for severe hypertrophic cardiomyopathy in childrenTrametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...
Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...
Fintel on MSN15d
B of A Securities Upgrades Erasca (ERAS)Fintel reports that on January 7, 2025, B of A Securities upgraded their outlook for Erasca (NasdaqGS:ERAS) from Neutral to Buy. Analyst Price Forecast Suggests 84.78% Upside As of December 23, 2024, ...
The degree of complexity and crossover within MAPK signaling, and also shifts in pathways such as nuclear factor κB signaling, could also explain the modest effect of p38 inhibitors. The p38α ...
(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback